Designing prodrugs for the treatment of Parkinson's disease

Expert Opinion on Drug Discovery

Volumn 7, Issue 5, 2012, Pages 385-406

  Sozio, Piera ^a   Cerasa, Laura Serafina ^a   Abbadessa, Anna ^a   Di Stefano, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Bloodbrain barrier; Dopamine; l Dopa; Parkinson's disease; Prodrugs

Indexed keywords

2 AMINO 6,7 DIHYDROXYTETRALIN; 4,5,5A,6,7,11B HEXAHYDRO 9,10 DIHYDROXY 2 PROPYL 3 THIA 5 AZACYCLOPENT 1 ENA[C]PHENANTHRENE; ADROGOLIDE; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENZATROPINE; BIPERIDEN; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DIHYDROPYRIDINE; DIPIVEFRINE; ETILEVODOPA; LEVODOPA; LEVODOPA METHYL ESTER; LISURIDE; PD 148903; PRECLAMOL; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; XP 21279;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG OXIDATION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSPORT; DYSKINESIA; ENZYMATIC DEGRADATION; HUMAN; LIPID SOLUBILITY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NEOSTRIATUM; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ANIMALS; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; CATECHOL O-METHYLTRANSFERASE; DOPAMINE AGONISTS; DRUG DESIGN; HUMANS; LEVODOPA; MICE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PRODRUGS; RATS;

EID: 84860358952     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.677025     Document Type: Review

References (122)

1. Grosset DG, Grosset KA, Okun MS, et al. Clinician's Desk Reference of Parkinson's Disease. Manson Publishing, LONDON; 2009
2. Savica R, Rocca WA, Ahlskog JE. When does Parkinson's Disease start? Arch Neurol 2010;67:798-801
3. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: Development, composition and regulation. Vascul Pharmacol 2002;38:323-37 (Pubitemid 36398254)
4. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002;200:629-38 (Pubitemid 34823054)
5. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003;61:40-78
6. Rautio J, Laine K, Gynther M, et al. Prodrug Approaches for CNS Delivery. AAPS J 2008;10:92-102
7. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discoveryand development. Pharm Res 2007;24:1745-58 (Pubitemid 47206624)
8. Pardridge WM, Oldendorf WH, Cancilla P, et al. Blood-brain barrier: Interface between internal medicine and the brain. Ann Intern Med 1986;105:82-95 (Pubitemid 16097930)
9. Pardridge WM. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 2003;3:90-105
10. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev 2006;7:41-53 (Pubitemid 41828930)
11. Malakoutikhah M, Teixido M, Giralt E. Shuttle-mediated drug delivery to the brain. Angew Chem Int Ed 2011;50:7998-8014
12. Terasaki T, Hosoya K. The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev 1999;36:195-209 (Pubitemid 29121972)
13. Celia C, Cosco D, Paolino D, et al. Nanoparticulate Devices for Brain Drug Delivery. Med Res Rev 2011;31:716-56
14. Denora N, Trapani A, Laquintana V, et al. Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain. Curr Top Med Chem 2009;9:182-96
15. Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Des 2009;15:2236-50
16. Pavan B, Dalpiaz A, Ciliberti N, et al. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 2008;13:1035-65
17. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12:54-61 (Pubitemid 46014479)
18. Oldendorf WH, Hyman S, Braun L, et al. Blood-brain barrier: Penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 1972;178:984-6
19. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 1999;36:229-54 (Pubitemid 29121974)
20. Bodor N, Buchwald P. Barriers to remember: Brain-Targeting chemical delivery systems and Alzheimer's disease. Drug Discov Today 2002;7:766-74 (Pubitemid 34828174)
21. Anderson BD. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 1996;19:171-202 (Pubitemid 26191620)
22. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007;24:1745-58 (Pubitemid 47206624)
23. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000;89:1371-88
24. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-Target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51:347-72 (Pubitemid 351252260)
25. Blandini F, Greenamyre JT. Protective and symptomatic strategies for therapy of Parkinson's. Drugs Today 1999;35:473-83 (Pubitemid 29361812)
26. Bodor N, Farag HH. Improved delivery through biological membranes. 13. Brain specific delivery of dopamine with a dihydropyridine-pyridinium salt type redox delivery system. J Med Chem 1983;26:528-34 (Pubitemid 13162296)
27. Kao HD, Traboulsi A, Itoh S, et al. Enhancement of the systemic and CNS Specific delivery of L-Dopa by the nasal administration of its water. Soluble prodrugs. Pharm Res 2000;17:978-84
28. Arica B, Kas HS, Moghdam A, et al. Carbidopa, Carbidopa/levodopa-loaded biodegradable microspheres: In vivo evaluation on experimental Parkinsonism in rats. J Control Release 2005;102:689-97 (Pubitemid 40170211)
29. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-44 (Pubitemid 16056209)
30. Hardie R, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. Brain 1984;107:487-506
31. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131-6 (Pubitemid 14068582)
32. Nutt JG, Carter JH, Lea ES, et al. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997;12:285-92 (Pubitemid 27216124)
33. Di Stefano A, Sozio P, Cerasa LS, et al. L-Dopa Prodrugs: An overview of trends for improving Parkinson's disease treatment. Curr Pharm Des 2011;17:3482-93
34. Hauser RA. Early Pharmacologic treatment in Parkinson's disease. Am J Manag Care 2010;16:S100-7
35. Di Stefano A, Sozio P, Iannitelli A, et al. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin Drug Deliv 2009;6:389-404
36. Bodor N, Sloan KB, Higuchi T, et al. Improved delivery through biological membranes 4: Prodrugs of L-dopa. J Med Chem 1977;20:1435-45 (Pubitemid 8209552)
37. Marrel C, Boss G, Van DeWaterbeemd H, et al. L-Dopa esters as potential prodrugs. Eur J Med Chem Chim Ther 1985;20:459-65
38. Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-Dopa methyl ester-A. candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol 1984;7:89-98 (Pubitemid 14138570)
39. Garzon-Aburbeh A, Poupaert JH, Claesen M, et al. A lymphotropic prodrug of L-dopa: Synthesis, pharmacological properties, and pharmacokinetic behaviour of 1, 3-dihexadecanoyl-2-[(S)-2-Amino-3- (3,4-dihydroxyphenyl)propanoyl] propane-1,2,3-Triol. J Med Chem 1986;29:687-91 (Pubitemid 16034677)
40. Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-dopa esters as potential prodrugs: Effect on brain concentration of dopamine metabolites in reserpinized mice. J Pharm Pharmacol 1987;39:809-18 (Pubitemid 18012990)
41. Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-dopa esters as potential prodrugs: Behavioural activity in experimental models of Parkinson's disease. J Pharm Pharmacol 1987;39:627-35 (Pubitemid 17116308)
42. Ihara M, Tsuchiya Y, Sawasaki Y, et al. New potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. J Pharm Sci 1989;78:525-9 (Pubitemid 20099187)
43. Ihara M, Nakajima S, Hisaka A, et al. Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3- (3-hydroxy-4-pivaloyloxyphenyl)alanine. J Pharm Sci 1990;79:703-8 (Pubitemid 20250888)
44. Stocchi F, Ruggieri S, Carta A, et al. Intravenous boluses and continuous infusions of L-DOPA methyl ester in fluctuating patients with Parkinson's disease. Mov Disord 1992;7:249-56
45. Djaldetti R, E, Melamed Levodopa ethylester: A novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996;39:400-4
46. Brime B, Ballesteros MP, Frutos P. Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration. J Microencapsul 2000;17:777-84
47. Xiang JN, Zhou CX, Yao F, et al. Inventors. Xenoport, Inc., assignee. Catechol protected levodopa diester prodrugs, compositions, and methods of use. WO2008079387; 2008
48. Xenoport website. Available from: Www: xenoport.com/research-development/ xp21279.htm
49. Atlas D. L-Dopa Amide derivatives and uses thereof. WO2004069146; 2004
50. Jiang W, Lv L, Zhou S, et al. Simultaneous determination of l-dopa and its prodrug (S)-4-(2-Acetamido-3-ethoxy-3-oxopropyl)-1,2-phenylene diacetate in rat plasma by high-performance liquid chromatography-Tandem mass spectrometry and its application in a pharmacokinetic study. J Pharm Biomed Anal 2010;53:751-4
51. Zhou T, Hider RC, Jenner P, et al. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. Eur J Med Chem 2010;45:4035-42
52. Denora N, Laquintana V, Lopedota A, et al. Novel L-Dopa and dopamine prodrugs containing a 2-Phenyl imidazopyridine moiety. Pharm Res 2007;24:1309-24 (Pubitemid 46870596)
53. Eltayb A, Wademberg MLG, Svensson TH. Enhanced cortical dopamine output and antipsycotic-like effect of raclopride with adjunctive low-dose L-Dopa. Biol Psychiatry 2005;58:337-43 (Pubitemid 41133628)
54. Langlois M, Quintard D, Abalain C. Synthesis of symmetrical pseudopeptides as potential inhibitors of the human immunodeficiency virus-1 protease. Eur J Med Chem 1994;29:639-47 (Pubitemid 24319783)
55. Christiaans JAM, Timmerman H. Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule. Eur J Pharm Sci 1996;4:1-22 (Pubitemid 26016569)
56. Mahfouz NM, Aboul-Fadl T, Diab AK. Metronidazole twin ester prodrugs: Synthesis, physicochemical properties, hydrolysis kinetics and antigiardial activity. Eur J Med Chem 1998;33:675-83 (Pubitemid 29161317)
57. Giannola LI, Giammona G, Alotta R. Pro-drugs of isoniazid: Synthesis and diffusion characteristics of acyl derivatives. Pharmazie 1992;47:423-5
58. Ducho C, Gorbig U, Jessel S, et al. BiscycloSal-d4T-monophosphates: Drugs that deliver two molecules of bioactive nucleotides. J Med Chem 2007;50:1335-46 (Pubitemid 46496332)
59. Felix AM, Winter DP, Wang SS, et al. Synthesis and antireserpine activity of peptides of L-Dopa. J Med Chem 1974;17:422-6
60. Di Stefano A, Mosciatti B, Cingolani GM, et al. Dimeric L-Dopa derivatives as potential prodrugs. Bioorg Med Chem Lett 2001;11:1085-8 (Pubitemid 32319987)
61. Cannazza G, Di Stefano A, Mosciatti B, et al. Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC. J Pharm Biomed Anal 2005;36:1079-84 (Pubitemid 40037829)
62. Di Stefano A, Carafa M, Sozio P, et al. Evaluation of rat striatal l-dopa and DA concentration after intraperitoneal administration of l-dopa prodrugs in liposomal formulations. J Control Release 2004;99:293-300 (Pubitemid 39222114)
63. Di Stefano A, Sozio P, Iannitelli A, et al. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation. J Drug Target 2006;14:652-61 (Pubitemid 44712361)
64. Cingolani GM, Di Stefano A, Mosciatti B, et al. Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa. Bioorg Med Chem Lett 2000;10:1385-8 (Pubitemid 30391975)
65. Giorgioni G, Claudi F, Ruggieri S, et al. Design, synthesis and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs. Bioorg Med Chem 2010;18:1834-43
66. Rasmussen GJ, Bundgaard H. Prodrugs of peptides. 15. 4-Imidazolidinone prodrug derivatives of enkephalins to prevent aminopeptidase-catalyzed metabolism in plasma and absorptive mucosae. Int J Pharm 1991;76:113-22
67. Ishikura T, Senou T, Ishihara H, et al. Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds. Int J Pharm 1995;116:51-63
68. Chemuturi NV, Donovan MD. Role of organic cation transporters in dopamine uptake across olfactory and nasal respiratory tissues. Mol Pharm 2007;4:936-42
69. Casagrande C, Ferrari G. 3,4-0-diacyl derivatives of dopamine. Il Farmaco 1973;28:143-8
70. Borgman RJ, McPhillips JJ, Stitzel RE. Synthesis and pharmacology of centrally acting dopamine derivatives and analogs in relation to Parkinson's disease. J Med Chem 1973;16:630-3
71. Bodor N, Farag HH, Brewster ME. Sitespecific, sustained release of drugs to the brain. Science 1981;214:1370-2 (Pubitemid 12135128)
72. Prokai L, Prokai-Tatrai K, Bodor N. Targeting drugs to the brain by redox chemical delivery systems. Med Res Rev 2000;20:367-416
73. Carelli V, Liberatore F, Scipione L, et al. New system for the specific delivery and sustained release of dopamine to the brain. J Control Release 1996;42:209-16 (Pubitemid 26338596)
74. Missale C, Nash SR, Robinson S, et al. Dopamine receptors: From structure to function. Physiol Rev 1998;78:189-225 (Pubitemid 28070979)
75. Uitti RY, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996;5:369-88 (Pubitemid 26173239)
76. Maratos EC, Jackson MJ, Pearce RK, et al. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 2001;16:631-41 (Pubitemid 36040842)
77. Giardina WJ, Williams M. Adrogolide HCl (ABT-431; DAS-431), a Prodrug of the Dopamine D1 Receptor Agonist, A-86929: Preclinical Pharmacology and Clinical Data. CNS Drug Rev 2001;7:305-16 (Pubitemid 34016087)
78. Shiosaki K, Jenner P, Asin KE, et al. ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: In vitro characterization and effects in animal models of Parkinson's disease. J Pharmacol Exp Ther 1996;276:150-60 (Pubitemid 26151536)
79. Rascol O, Blin O, Thalamas C, et al. ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 1999;45:736-41 (Pubitemid 29260750)
80. Baldessarini RJ, Walton KG, Borgman RJ. Esters of apomorphine and N,N-dimethyldopamine as agonists of dopamine receptors in the rat brain in vivo. Neuropharmacol 1975;14:725-31
81. Borgman RJ, Baldessarini RJ, Walton KG. Diester derivatives as apomorphine prodrugs. J. Med Chem 1976;19:717-19
82. Baldessarini RJ, Kula NS, Walton KG, et al. Hydrolysis of diester prodrugs of apomorphine. Biochem Pharmacol 1977;26:1749-56 (Pubitemid 8163434)
83. Dijkstra D, Venhuis BJ, Wikstrom HV, et al. Method for treating Parkinson's disease by administering of (-)-5-keto-2-N,N-di- propylaminotetrahydrotetralin. WO0128977A1; 2001
84. Venhuis BJ, Wikstrom HV, Rodenhuis N, et al. A new type of prodrug of catecholamines - An opportunity to improve the treatment of Parkinson's Disease. J Med Chem 2002;45:2349-51 (Pubitemid 34595203)
85. Liu KS, Sung KC, Al-Suwayeh SA, et al. Enhancement of transdermal apomorphine delivery with a diester prodrug strategy. Eur J Pharm Biopharm 2011;78:422-31
86. Tsai MJ, Huang YB, Wu PC, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: Pharmacokinetic and behavioural evaluations. J Pharm Sci 2011;100:547-57
87. Venhuis BJ, Dijkstra D, Wustrow DJ, et al. Orally active analogues of the dopaminergic prodrug 6-(N,N-di-npropylamino)-3,4,5,6,7,8-hexahydro- 2Hnaphthalen-1-one. synthesis and pharmacological activity. J Med Chem 2003;46:584-90 (Pubitemid 36182759)
88. Venhuis BJ, Dijkstra D, Wustrow D, et al. Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-Di-npropylamino)-3,4,5,6,7,8-hexahydro- 2Hnaphthalen-1-one. synthesis and pharmacological activity. J Med Chem 2003;46:4136-40 (Pubitemid 37138505)
89. Hes J, Sternson LA. The metabolism of acetophenone oxime in rat liver homogenates. Drug Metab Dispos 1974;2:345-50
90. Axelrod LR, Miller LL. The metabolism of testosterone in the isolated perfused dog liver. J Biol Chem 1956;219:455-61
91. Liu D, Wikstroem HV, Dijkstra D, et al. Extremely potent orally active benzo[g] quinoline analogue of the dopaminergic prodrug: 6-(N,N-Di-n-propyl) amino-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. J Med Chem 2006;49:1494-8 (Pubitemid 43271902)
92. Liu D, Venhuis BJ, Wikstrom HV, et al. Synthesis of supposed enone prodrugs of apomorphine and N-propyl-norapomorphine. Tetrahedron 2007;63:7264-70 (Pubitemid 46891508)
93. Woodruff GN, Elkhawad AO, Crossman AR, et al. Further evidence for the stimulation of rat brain dopamine receptors by a cyclic analogue of dopamine. J Pharm Pharmacol 1974;26:740-1
94. Woodruff GN, Elkhawad AO, Pinder RM. Long lasting stimulation of locomotor activity produced by the intraventricular injection of a cyclic analogue of dopamine into conscious mice. Eur J Pharmacol 1974;25:80-6
95. Westerink BH, Dijkstra D, Feenstra MG, et al. Dopaminergic prodrugs: Brain concentrations and neurochemical effects of 5,6- and 6,7-ADTN after administration as dibenzoyl esters. Eur J Pharmacol 1980;61:7-15 (Pubitemid 10178020)
96. Thorberg SO, Berg S, Lundstrom J, et al. Carbamate ester derivatives as potential prodrugs of the presynaptic dopamine autoreceptor agonist (-)-3- (3-hydroxyphenyl)-N-propylpiperidine. J Med Chem 1987;30:2008-12 (Pubitemid 18046056)
97. den Daas I, Tepper PG, Horn AS. Improvement of the oral bioavailability of the selective dopamine agonist N-0437 in rats: The in vitro and in vivo activity of eight ester prodrugs. Naunyn Schmiedebergs Arch Pharmacol 1990;341:186-91 (Pubitemid 20102206)
98. den Daas I, Tepper PG, Rollema H, et al. Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: Comparison with oral administration in the 6-OHDA turning model. Naunyn Schmiedebergs Arch Pharmacol 1990;342:655-9
99. Pavan B, Dalpiaz A. Prodrugs and endogenous transporters: Are they suitable tools for drug targeting into the central nervous system? Curr Pharm Des 2011;17:3560-76
100. Gynther M, Ropponen J, Laine K, et al. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rat. J Med Chem 2009;52:3348-53
101. More SS, Vince R. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs. J Med Chem 2008;51:4581-8
102. Wang H, Lee J, Tsai M, et al. Synthesis and Pharmacological activities of a novel tripeptide mimetic dopamine prodrug. Bioorg Med Chem Lett 1995;5:2195-8
103. Bai JPF, Hu M, Subramanian P, et al. Utilization of peptide carrier system to improve intestinal absorption: Targeting prolidase as a prodrug-converting enzyme. J Pharm Sci 1992;81:113-16
104. Pinnen F, Cacciatore I, Cornacchia C, et al. Codrugs linking L-Dopa and Sulfur-containing antioxidants: New pharmacological tools against Parkinson's disease. J Med Chem 2009;52:559-63
105. Minelli A, Conte C, Prudenzi E, et al. N-Acetyl-L-Methionyl-L-Dopa-Methyl Ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity. Free Radic Biol Med 2010;49:31-9
106. Pinnen F, Cacciatore I, Cornacchia C, et al. Synthesis and study of L-Dopa-Glutathione codrugs as New anti-Parkinson agents with free radical scavenging properties. J Med Chem 2007;50:2506-15 (Pubitemid 46799262)
107. Bobrowski K, Hug GL, Pogocki D, et al. Sulfur radical cation-peptide bond complex in the one-electron oxidation of S-methylglutathione. J Am Chem Soc 2007;129:9236-45 (Pubitemid 47171872)
108. Pinnen F, Cacciatore I, Cornacchia C, et al. CNS delivery of L-Dopa by a new Hybrid Glutathione-Methionine peptidomimetic prodrug. Amino Acids 2012;42:261-9
109. Anderson BD. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 1996;19:171-202 (Pubitemid 26191620)
110. Prokai L. Peptide drug delivery into the central nervous system. Prog Drug Res 1998;51:95-131 (Pubitemid 28511542)
111. Chavis C, Grodenic F, Imbach JL. Ribosides et derives de la L-methyl dopa et de la L-dopa. Eur J Med Chem Chim Ther 1981;16:219-27 (Pubitemid 11091927)
112. Bonina F, Puglia C, Rimoli MG, et al. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: Synthesis, pharmacological activity and in vitro stability studies. J Drug Target 2003;11:25-36
113. Yoon S, Fulton DB, Robyt JF. Synthesis of dopamine and L-DOPA-Alphaglycosides by reaction with cyclomaltohexaose catalyzed by cyclomaltodextrin glucanyltransferase. Carbohydr Res 2009;344:2349-56
114. Savolainen J, Leppanen J, Forsberg M, et al. Synthesis and in vitro/in vivo evaluation of novel oral N-Alkyl and N, N-dialkylcarbamate esters of entacapone. Life Sci 2000;67:205-16 (Pubitemid 30414487)
115. Leppanen J, Huuskonen J, Nevalainen T, et al. Design and Synthesis of a Novel L-Dopa-Entacapone Codrug. J Med Chem 2002;45:1379-82 (Pubitemid 34263574)
116. Rautio J, Leppanen J, Lehtonen M, et al. Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor. Bioorg Med Chem Lett 2010;20:2614-16
117. Di Stefano A, Sozio P, Iannitelli A, et al. Synthesis and preliminary evaluation of L-Dopa/Benserazide conjugates as dual acting codrugs. Lett Drug Des Discov 2006;3:747-52 (Pubitemid 46058745)
118. Giannola LI, De Caro V, Giandalia G, et al. Synthesis and in vitro studies on a potential dopamine prodrug. Pharmazie 2008;63:704-10
119. Fernandez C, Nieto O, Rivas E, et al. Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr Res 2000;327:353-65 (Pubitemid 30456325)
120. Fernandez C, Nieto O, Fontenla JA, et al. Org. Synthesis of glycosyl derivatives as dopamine prodrugs: Interaction with glucose carrier GLUT-1. Biomol Chem 2003;1:767-71
121. Ruocco LA, Viggiano D, Viggiano A, et al. Galactosilated dopamine enters into the brain, blocks mesocorticolimbic system and modulates activity and scanning time in Naples high excitability rats. Neuroscience 2008;152:234-44
122. Juncos JL, Mouradian MM, Fabbrini G, et al. Levodopa methyl ester treatment of Parkinson's disease. Neurology 1987;37:1242-5 (Pubitemid 17130766)